本文源自：金融界AI电报 开拓药业公告，于2026年1月21日，公司全资附属公司开禧香港有限公司与北京德开医药科技有限公司 订立独家销售代理协议，内容有关公司防脱泡沫剂产品在中国内地市场的销售代理及市场推广。 ...

Core Viewpoint - The announcement highlights a strategic partnership between the company and Beijing Dekai Pharmaceutical Technology Co., Ltd. for the exclusive sales agency of the company's anti-foaming agent products in the mainland China market [1] Group 1: Partnership Details - The company’s wholly-owned subsidiary, Kaixi Hong Kong Limited, has entered into an exclusive sales agency agreement with Dekai Pharmaceutical [1] - The agreement focuses on the sales agency and market promotion of the company's anti-foaming agent products in mainland China [1] Group 2: Strategic Objectives - Both parties aim to leverage their respective advantages and resources to establish a close cooperative relationship [1] - The collaboration is intended to drive business development and product extension, achieving complementary advantages and synergistic growth [1]